August 9, 2022

Bavarian Nordic’s Jynneos® has been approved as a vaccine for individuals 18 years of age and older who are determined to be at high risk for monkeypox infection.

  • Recommended dosing is two doses (0.5 mL each) 4 weeks apart, both taken subcutaneously.
  • The FDA issued an emergency use authorization (EUA) for Jynneos.
August 18, 2022

U.S. FDA Approves First Cetrotide Generic

Read More
August 17, 2022

Zynteglo Approved as Gene Therapy for Rare Blood Disorder

Read More